Ionis Pharmaceuticals, Inc.
IONS
Hisse Senetlerindeki Sıralama
#2572
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Hisse Fiyatı
$44.84
Piyasa Değeri
$7.45B
Değişim (1 gün)
1.04%
Değişim (1 yıl)
-39.03%
Ülke
US
Ticaret Ionis Pharmaceuticals, Inc. (IONS)
Kategori
Healthcare
Ionis Pharmaceuticals, Inc. (IONS) için tedavüldeki hisse sayısı
June 2026 itibarıyla tedavüldeki hisse sayısı: 165.42M
Ionis Pharmaceuticals, Inc. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 165.42M'dir. December 2023 sonunda şirketin 143.00M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
Ionis Pharmaceuticals, Inc. (IONS) için 2000 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 165.42M | 10.64% |
| 2024 | 149.51M | 4.56% |
| 2023 | 143.00M | 0.81% |
| 2022 | 141.85M | 0.59% |
| 2021 | 141.02M | 1.01% |
| 2020 | 139.61M | -0.28% |
| 2019 | 140.00M | 5.80% |
| 2018 | 132.32M | 6.70% |
| 2017 | 124.02M | 2.66% |
| 2016 | 120.80M | 1.26% |
| 2015 | 119.29M | 1.36% |
| 2014 | 117.69M | 6.51% |
| 2013 | 110.50M | 9.87% |
| 2012 | 100.58M | 0.92% |
| 2011 | 99.66M | 0.52% |
| 2010 | 99.14M | 1.05% |
| 2009 | 98.11M | 3.75% |
| 2008 | 94.57M | 12.93% |
| 2007 | 83.74M | 12.69% |
| 2006 | 74.31M | 18.18% |
| 2005 | 62.88M | 11.01% |
| 2004 | 56.64M | 2.13% |
| 2003 | 55.46M | 1.80% |
| 2002 | 54.48M | 23.51% |
| 2001 | 44.11M | 19.14% |
| 2000 | 37.02M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 253.90M | 53.49% |
US
|
|
| 396.00M | 139.39% |
US
|
|
| 478.91M | 189.51% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -62.41% |
NL
|
